CD8 Alpha antibody | YTS105.18
Rat anti Mouse CD8 antibody, clone YTS105.18 (MCA1108G) used to demonstrate the presence of CD8 expressing T cells in the ilium of neonatal rats by immunofluorescence on cryosections.
Recruitment of inflammatory cells in the intestine of neonates after CpG-ODN treatment. Eight-day-old neonatal mice received 20 μg/g of CpG-ODN orally. Twenty-four hours after treatment, ilea were removed to analyze the recruitment of inflammatory cells by immunohistology. Six to ten neonates from different litters (5 sections for each animal) per group were analyzed. Data were analyzed by non-parametric Mann-Whitney test.
From: Lacroix-Lamandé S, Rochereau N, Mancassola R, Barrier M, Clauzon A, et al. (2009)
Neonate Intestinal Immune Response to CpG Oligodeoxynucleotide Stimulation.
PLoS One. 2009 Dec 14;4(12):e8291.
This image is from an open access article distributed under the terms of a Creative Commons Attribution License.
Rat anti Mouse CD8 antibody, clone YTS105.18 (MCA1108G) used to identify infiltrating CD8 positive T cells in tumors by immunofluorescence.
NKG2D-dependent infiltration of CD8+T cells into tumors. Tumors were collected from mice that had received one of the four standard treatments: control DNA, Dox plus control DNA, IL-12, Dox plus IL-12 (n = 3 per treatment group). (B) NKG2D/CD8–positive cells in tumor sections by treatment received. Frozen tumor sections were stained with biotin anti-mouse NKG2D, anti-mouse CD8, or corresponding isotype control antibodies, then with streptavidin-conjugated Alexa fluor 594 or Alexa fluor 488 secondary antibodies. Data shown are representative of three independent experiments. The scale bar is equivalent to 100 μm.
From: CD8+T cell-specific induction of NKG2D receptor by doxorubicin plus interleukin-12 and its contribution to CD8+T cell accumulation in tumors.From: Hu J, Zhu S, Xia X, Zhang L, Kleinerman ES, Li S.
CD8+T cell-specific induction of NKG2D receptor by doxorubicin plus interleukin-12 and its contribution to CD8+T cell accumulation in tumors.
Mol Cancer. 2014 Feb 24;13:34.
This image is from an open access article distributed under the terms of the Creative Commons Attribution License.
Rat anti Mouse CD8 antibody, clone YTS105.18 (MCA1108G) used to identify infiltrating CD8 positive T cells in tumors by immunofluorescence.
The effect of NK cell or CD8+T cell depletion on NKG2D-positive lymphocyte localization in tumors. Groups of mice (n = 3 per treatment group) were subjected to one of the four standard treatments: control DNA, Dox plus control DNA, IL-12, Dox plus IL-12. Tumor sections were stained as detailed in the Figure 3 legend. (A) Detection of NKG2D-positive cells in tumors from NK cell–depleted mice, (B) Absence of NKG2D-positive cells in CD8+T cell–depleted mice. Data shown are representative of three independent experiments. The scale bar is equivalent to 100 μm.
From: CD8+T cell-specific induction of NKG2D receptor by doxorubicin plus interleukin-12 and its contribution to CD8+T cell accumulation in tumors. From: Hu J, Zhu S, Xia X, Zhang L, Kleinerman ES, Li S.
Mol Cancer. 2014 Feb 24;13:34.
This image is from an open access article distributed under the terms of the Creative Commons Attribution License.
Rat anti Mouse CD8 antibody, clone YTS105.18 (MCA1108G) used to identify infiltrating CD8 positive T cells in tumors by immunofluorescence.
The effect of NKG2D-blocking antibody on NKG2D-positive CD8+T cells and CD8+T cell accumulation in tumors. 4T-1 tumor–bearing mice were subjected to one of two treatments: Dox plus IL-12 plus control IgG or Dox plus IL-12 plus NKG2D-blocking antibody (n = 3 per treatment). (A) NKG2D expression in CD8+T cells was determined as described for Figure 1 (n.s., not significant). (B) The presence of NKG2D/CD8–positive cells in tumor sections after the indicated treatments were determined as described for Figure 3.
From: CD8+T cell-specific induction of NKG2D receptor by doxorubicin plus interleukin-12 and its contribution to CD8+T cell accumulation in tumors.
Hu J, Zhu S, Xia X, Zhang L, Kleinerman ES, Li S.
Mol Cancer. 2014 Feb 24;13:34.
This image is from an open access article distributed under the terms of the Creative Commons Attribution License.
Rat anti Mouse CD8, clone YTS105.18 recognizes a non polymorphic epitope on the mouse CD8 alpha chain. This antibody has been reported to block MHC I dependent T cell responses in vitro and in vivo, and induces transplantation tolerance in combination with CD4 antibodies (Cobbold et al. 1990 & Wise et al. 1998).
Product Details
- Target Species
- Mouse
- Product Form
- Purified IgG - liquid
- Product Form
- Purified IgG - liquid
- Preparation
- Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
- Preparation
- Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Preservative Stabilisers
- None present
- Preservative Stabilisers
0.09% Sodium Azide - Carrier Free
- Yes
- Carrier Free
- Yes
- Immunogen
- Mouse spleen cells.
- Approx. Protein Concentrations
- IgG concentration 1 mg/ml
- Approx. Protein Concentrations
- IgG concentration 1 mg/ml
- Fusion Partners
- Spleen cells from an immunised DA rat were fused with cells of the rat Y3/Ag1.2.3. myeloma cell line.
Storage Information
- Storage
- Store at -20oC only.
This product should be stored undiluted.
Storage in frost-free freezers is not recommended. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use. - Storage
- Store at +4oC or at -20oC if preferred.
This product should be stored undiluted.
Storage in frost free freezers is not recommended. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use. - Guarantee
- 12 months from date of despatch
- Guarantee
- 12 months from date of despatch
More Information
- UniProt
- P01731
- Entrez Gene
- Cd8a
- GO Terms
- GO:0002456 T cell mediated immunity
- GO:0016021 integral to membrane
- GO:0007166 cell surface receptor linked signaling pathway
- GO:0009897 external side of plasma membrane
- GO:0042803 protein homodimerization activity
- GO:0045065 cytotoxic T cell differentiation
- GO:0050850 positive regulation of calcium-mediated signaling
- Regulatory
- For research purposes only
Applications of CD8 Alpha antibody
| Application Name | Verified | Min Dilution | Max Dilution |
|---|---|---|---|
| Flow Cytometry | 1/50 | 1/100 | |
| Immunofluorescence | |||
| Immunohistology - Frozen | |||
| Flow Cytometry | 1/50 | 1/100 | |
| Immunofluorescence | |||
| Immunohistology - Frozen |
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.
- Flow Cytometry
- Use 10ul of the suggested working dilution to label 106 cells in 100ul.
- Flow Cytometry
- Use 10ul of the suggested working dilution to label 106 cells in 100ul.
Copyright © 2020 Bio-Rad Antibodies (formerly AbD Serotec)
Secondary Antibodies Available
Negative Isotype Controls Available
| Description | Product Code | Applications | Pack Size | List Price | Quantity |
|---|---|---|---|---|---|
| Rat IgG2a Negative Control:Low Endotoxin | MCA1212EL | F | 0.5 mg |
|
|
| Rat IgG2a Negative Control | MCA1212 | E F | 1 ml |
|
Product Specific References
References for CD8 Alpha antibody
-
Qin, S.X. et al. (1990) Induction of tolerance in peripheral T cells with monoclonal antibodies.
Eur J Immunol. 20 (12): 2737-45. -
Cobbold, S.P. et al. (1990) The induction of skin graft tolerance in major histocompatibility complex-mismatched or primed recipients: primed T cells can be tolerized in the periphery with anti-CD4 and anti-CD8 antibodies.
Eur J Immunol. 20 (12): 2747-55. -
Wise, M.P. et al. (1998) Linked suppression of skin graft rejection can operate through indirect recognition.
J Immunol. 161 (11): 5813-6. -
Lacroix-Lamande, S. et al. (2009) Neonate intestinal immune response to CpG oligodeoxynucleotide stimulation.
PLoS One. 4: 1-8. -
Auray, G. et al. (2007) Involvement of intestinal epithelial cells in dendritic cell recruitment during C. parvum infection
Microbes Infect. 9: 574-82. -
Sroga, J.M. et al. (2003) Rats and mice exhibit distinct inflammatory reactions after spinal cord injury.
J Comp Neurol. 462: 223-40. -
Karlsson, M.R. et al. (2010) Hypersensitivity and oral tolerance in the absence of a secretory immune system.
Allergy. 65: 561-70. -
Himoudi, N. et al. (2007) Development of anti-PAX3 immune responses; a target for cancer immunotherapy
Cancer Immunol Immunother. 56: 1381-95. -
Nakashima, H. et al. (2011) A Novel Combination Immunotherapy for Cancer by IL-13Rα2-Targeted DNA Vaccine and Immunotoxin in Murine Tumor Models.
J Immunol. 187: 4935-46. -
Shaw, T.N. et al. (2015) Perivascular Arrest of CD8+ T Cells Is a Signature of Experimental Cerebral Malaria.
PLoS Pathog. 11 (11): e1005210.
